Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung Ju Ahn, James C.H. Yang, Ji Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander Spira, Scott N. Gettinger, Marcello Tiseo, Huamao M. Lin, Neeraj Gupta, Michael J. Hanley, Quanhong NiPingkuan Zhang, Sanjay Popat

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences